|
Palo Alto, CA, April 29, 2005 — Telik, Inc. (Nasdaq: TELK) announced that its first quarter 2005 financial results will be released on Thursday, May 5, 2005 after the close of the financial markets. The company’s quarterly conference call and webcast will be held on Friday, May 13, 2005 at 4:30 p.m. Eastern time (1:30 p.m. Pacific time) during the American Society of Clinical Oncology Annual Meeting.
The May 13 conference call and webcast will be accessible via Telik’s website at www.telik.com or by telephone at 877-209-0397 or 612-332-1025. An archive of the conference call will be available on the Telik website from approximately 8:00 p.m. Eastern time on May 13 through May 20, 2005, or by telephone at 800-475-6701 or 320-365-3844, access code 780992.
Telik, Inc. of Palo Alto, CA is a biopharmaceutical company working to discover, develop and commercialize small molecule drugs to treat serious diseases. The company’s most advanced drug development candidate is TELCYTA™ (TLK286), a tumor-activated small molecule product candidate which is in three Phase 3 registration trials in advanced ovarian and non-small cell lung cancer. Telik’s product candidates were discovered using its proprietary drug discovery technology, TRAP, which enables the rapid and efficient discovery of small molecule drug candidates. Additional information is available at www.telik.com.
###
Contact:
Carol DeGuzman
Senior Director, Corporate Communications
Telik, Inc.
Tel 650-845-7728
Email cdeguzman@telik.com
Go to: 2005 Press Releases2004
Press Releases
2003
Press ReleasesEvents |
